Gilead wins approval for HIV drug as prophylactic

(Reuters) – Gilead Sciences Inc said on Monday it has won U.S. approval to market its drug Truvada as a prophylactic treatment to reduce the risk of infection with HIV, the virus that causes AIDS. The approval marks the first time an HIV drug has been approved for people who have not yet been infected. It is approved for those at high risk of infection and those who may engage in sexual activity with HIV-infected partners. The drug, taken daily, is to be used in combination with safer sex practices to reduce the risk of sexually acquired HIV infection in adults at high risk. …
Sexual Health News Headlines – Yahoo! News